Eisai Opens Representative Office in Dubai

News provided by

Eisai Europe Limited

17 Apr, 2012, 23:01 GMT

HATFIELD, England, April 18, 2012 /PRNewswire/ --

 

New EMEA Dubai Office Part of Expansion Plans into Middle East and Parts of Africa

PRESS RELEASE NOT INTENDED FOR DUBAI MEDIA

Japanese company Eisai is expanding its geographical and patient reach by opening a new regional representative office in Dubai today.

The Eisai EMEA (Europe, Middle East and Africa) Dubai branch office, located in Dubai Healthcare City (DHCC), marks the increased global presence of the company and supports Eisai's vision to secure patient access to innovative and novel treatments not previously available to them. This forms part of the company's new organisational structure as set out in its mid-term strategic plan HAYABUSA.  

"Eisai's entry into the Middle East and Africa region enforces our wider plan of increasing access to medicines based on a strategy of affordability, availability, adoption and architecture," points out the new EMEA Regional Director, Ayman ElDeeb.  "This expansion is an opportunity to make our currently marketed and pipeline products available, as well as to explore in-licensing of products which may match specific patient needs in the region."

Eisai has already launched Methycobal® (mecobalamin), a treatment for peripheral neuropathy, in Saudi Arabia, the United Arab Emirates and other countries in the Middle East. The company now plans to register and introduce selected oncology and neurology products to the region, including the new metastatic breast cancer treatment Halaven® (eribulin) and a novel agent for the treatment of epilepsy.  This move further supports Eisai's human health care (hhc) mission to address unmet medical needs and contribute to the health and well-being of people worldwide.

Eisai's commitment to establish a strong presence in the Middle East, North and South Africa is further seen by the establishment of a new EMEA business headquarters based in Hatfield, UK.  The £100m facility, which opened in 2009, initially focused solely in Europe, but now supports the company's growing EMEA business.  Eisai Co., Ltd. was established in 1941 in Tokyo, Japan where our global headquarters are located. In 2011, Eisai hit a major milestone by celebrating its 70th anniversary.

Eisai is proud to be working with DHCC on the expansion into the Middle East and parts of Africa. DHCC was launch in 2002 and it combines the leading expertise of medical institutions and pre-eminent healthcare providers to deliver the A to Z of medical services.

Notes to Editors

About Eisai

Eisai is one of the world's leading R&D-based pharmaceutical companies and has defined its corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call human health care (hhc). Eisai recently expanded their UK Hatfield facility which now supports the company's growing European, Middle Eastern and African (EMEA) business.

Eisai concentrates its R&D activities in three key areas:

  • Neuroscience, including: Alzheimer's disease, multiple sclerosis, neuropathic pain, epilepsy, depression
  • Oncology including: anticancer therapies; tumour regression, tumour suppression, antibodies, etc and supportive cancer therapies; pain relief, nausea
  • Vascular/Immunological reaction including: acute coronary syndrome, atherothrombotic disease, rheumatoid arthritis, psoriasis, Crohn's disease

With operations in the U.S., Asia, Europe and its domestic home market of Japan, Eisai employs more than 11,000 people worldwide. In Europe, Eisai undertakes sales and marketing operations in over 20 markets, including the United Kingdom, France, Germany, Italy, Spain, Switzerland, Sweden, Ireland, Austria, Denmark, Finland, Norway, Portugal, Iceland, Czech Republic, Slovakia, the Netherlands, and Belgium.

For further information please visit our web site http://www.eisai.com

About Eisai's Commitment to Neglected Tropical Diseases

Alongside other leading pharmaceutical companies, Eisai signed a declaration earlier this year in London with the Bill & Melinda Gates Foundation, the WHO, the US and UK governments, the World Bank and governments from neglected tropical disease (NTD) endemic countries to make a coordinated effort to eliminate 10 NTDs by 2020. Eisai is the only Japanese company to join the 'London Declaration'.

Eisai has also recently announced that it has discovered a potential treatment for Chagas disease and the UK Wellcome Trust is funding its development

About Eisai's Commitment to Improving Global Access to Medicines

Today, it is estimated that some 2.7 billion* people around the world live on US$ 2 or less per day. Most of these 2.7 billion people do not have access to essential health care and treatment despite the availability of effective medicines. This is an international challenge that needs to be solved through collaborations among governments, international organisations such as the WHO, non-governmental organisations and pharmaceutical companies.

In line with its human health care (hhc) mission, Eisai is committed to improving global access to medicines over the medium-to-long term through partnership strategies that involve working with governments, international organisations, private entities and non-profit organisations. Specifically, the company has developed and is implementing a five-target approach to improve access to medicines worldwide. The five key components are: product creations, strategic solutions, capacity building, quality innovation, and long-term investment.

For further information on Eisai's Access to Medicines initiatives, please visit the Access to Medicines page on the Eisai Global website: http://www.eisai.com/company/atm/index.html

* Source: World Bank (2005)

About Eisai's plan HAYABUSA

HAYABUSA is the name of Eisai's medium-term strategic plan, embarked on from April 2011. It aims for sales of 800 billion yen or more and operating profit of 200 billion yen or more by the end of the fiscal year of 2015.  In the HAYABUSA plan, Eisai will seek to establish a presence in each of the world's top 20 pharmaceutical markets in an effort to achieve its objective of making contributions to more than 500 million patients worldwide.  

Eisai in Oncology

Eisai is dedicated to discovering, developing and producing innovative oncology therapies that can make a difference and impact the lives of patients and their families. This passion for people is part of Eisai's human health care (hhc) mission, which strives for better understanding of the needs of patients and their families to increase the benefits health care provides. Our commitment to meaningful progress in oncology research, built on scientific expertise, is supported by a global capability to conduct discovery and preclinical research, and develop small molecules, therapeutic vaccines, and biologic and supportive care agents for cancer across multiple indications.

About Eisai in Epilepsy

Eisai is committed to developing and delivering highly beneficial new treatments to help improve the lives of people with epilepsy. The development of anti-epileptic drugs (AEDs) is a major strategic area for Eisai in the EMEA market. In the European Union and Switzerland, Eisai currently has three marketed treatments including:

  • Zonegran® (zonisamide) as adjunctive therapy in adult patients with partial-onset seizures, with or without secondary generalisation
  • Zebinix® (eslicarbazepine acetate) as adjunctive therapy in adult patients with partial-onset seizures, with or without secondary generalization
  • Inovelon® (rufinamide) for the adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome in patients >4 years